$$\rightleftharpoonup{xx}$$
$$\longleftharp{xx}$$,
$$\longrightharp{xx}$$,
Major depressive disorder (MDD) is the leading cause of mental disability worldwide, with an incidence that is increasing faster than anticipated. In 2001, the World Health Organization predicted that MDD would be the second most common disease in the world by 2020. However, it was already the second most common in 20131. In addition, current antidepressants have many limitations, including delayed effectivity, drug resistance, relapse, and various side effects2,3. Researchers must therefore develop more effective antidepressants. However, the ambiguous pathophysiology of MDD presents an obstacle to the development of novel antidepressants.
Long-term stress is the main risk factor for MDD. It can induce dysfunction in the hypothalamic-pituitary-adrenal (HPA) axis, which is also related to MDD etiology4,5. As described previously, the HPA axis plays a critical role in stress-induced psychiatric pathophysiology including depression and anxiety disorders by increasing corticosterone levels6,7,8,9. Many animal models have been based on sustained activation of the HPA axis, which is observed in patients with MDD4. Moreover, high glucocorticoids induced by chronic stress and subcutaneously injected glucocorticoids cause depressive behaviors along with neural cell death, atrophy of neuronal processes, and reduced adult neurogenesis in the brain of rodents10,11. Another important brain area associated with depression is the medial prefrontal cortex (mPFC). The mPFC plays a crucial role in controlling brain subregions, such as the hypothalamus and amygdala, that control emotional behavior and stress responses8,9. For instance, lesions in the dorsal mPFC induced HPA axis dysfunction and enhanced corticosterone secretion due to restraint stress12,13. A recent study also showed that repeated restraint stress increased corticosterone levels, which could be decreased by glutamine supplementation via glutamate-glutamine cycle between neurons and astrocyte in the mPFC9.
The first chronic stress paradigm used to study the etiology of MDD was suggested by Katz14. Willner et al. then proposed a chronic mild stress (CMS) model based on the findings of Katz. They confirmed that the model had predictive validity by observing that antidepressants restored CMS-induced anhedonic-like behavior15,16. Typically, the CMS model consists of a combination of various mild stresses, such as mild noise, cage tilting, wet bedding, altered light-dark cycles, cage shaking, forced swimming, and social defeat. The CMS model is widely utilized by researchers; however, this model is of poor replicability, and time- and energy-inefficient. Therefore, there is a growing demand for a standardized and simplified protocol for induction of depressive-like behavior and physiological analysis to evaluate depression. Compared to the CMS model, the chronic immobilization stress (CIS; also known as chronic restraint stress) model is simpler and more efficient; therefore, the CIS model can be widely used in chronic stress studies17,18,19,20,21,22,23,24. In addition, CIS can be used in both male and female mice to develop depressive behaviors25,26. During CIS, animals are placed in a body-fit sized cylinder for 1-8 hours per day for 2 or 4 weeks9,27,28. Of these, restraint stress condition for 2 hours per day for 2 weeks is sufficient to cause depressive behaviors with minimal pain in mice9,28. Under restraint conditions, blood corticosterone levels were rapidly increased9,28,29. Several studies have shown that the CIS model has predictive validity, confirming that CIS-induced depressive-like symptoms are restored by antidepressants19,20,30,31. Herein, we report the detailed procedures of CIS, as well as some behavioral and physiological outcomes after CIS in mice.